Disparities in Cardiovascular Disease Risk Among Hispanic Breast Cancer Survivors in a Population-Based Cohort.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ adverse effects
Breast Neoplasms
/ drug therapy
Cancer Survivors
/ statistics & numerical data
Cardiovascular Diseases
/ ethnology
Cohort Studies
Confidence Intervals
Female
Hispanic or Latino
/ statistics & numerical data
Humans
Lymphatic Diseases
/ ethnology
Middle Aged
Proportional Hazards Models
Registries
Risk Factors
Time Factors
Utah
White People
/ statistics & numerical data
Young Adult
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
01
09
2020
revised:
18
12
2020
accepted:
20
01
2021
entrez:
23
4
2021
pubmed:
24
4
2021
medline:
24
4
2021
Statut:
epublish
Résumé
Breast cancer is the leading cause of cancer death among Hispanic women. The aim of our study was to estimate cardiovascular disease (CVD) risk among Hispanic and non-Hispanic White (NHW) breast cancer survivors compared with their respective general population cohorts. Cohorts of 17 469 breast cancer survivors (1774 Hispanic and 15 695 NHW) in the Utah Cancer Registry diagnosed between 1997 and 2016, and 65 866 women (6209 Hispanic and 59 657 NHW) from the general population in the Utah Population Database were identified. Cox proportional hazards models were used to estimate hazard ratios (HRs) for CVD. The risk of diseases of the circulatory system was higher in Hispanic than NHW breast cancer survivors 1-5 years after cancer diagnosis, in comparison with their respective general population cohorts (HR We observed a risk difference for diseases of the circulatory system between Hispanic and NHW breast cancer survivors compared with their respective general population cohorts but only within the first 5 years of cancer diagnosis.
Sections du résumé
Background
Breast cancer is the leading cause of cancer death among Hispanic women. The aim of our study was to estimate cardiovascular disease (CVD) risk among Hispanic and non-Hispanic White (NHW) breast cancer survivors compared with their respective general population cohorts.
Methods
Cohorts of 17 469 breast cancer survivors (1774 Hispanic and 15 695 NHW) in the Utah Cancer Registry diagnosed between 1997 and 2016, and 65 866 women (6209 Hispanic and 59 657 NHW) from the general population in the Utah Population Database were identified. Cox proportional hazards models were used to estimate hazard ratios (HRs) for CVD.
Results
The risk of diseases of the circulatory system was higher in Hispanic than NHW breast cancer survivors 1-5 years after cancer diagnosis, in comparison with their respective general population cohorts (HR
Conclusions
We observed a risk difference for diseases of the circulatory system between Hispanic and NHW breast cancer survivors compared with their respective general population cohorts but only within the first 5 years of cancer diagnosis.
Identifiants
pubmed: 33889806
doi: 10.1093/jncics/pkab016
pii: pkab016
pmc: PMC8052955
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002538
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA185811
Pays : United States
Organisme : NCRR NIH HHS
ID : R01 RR021746
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press.
Références
BMC Public Health. 2019 Jan 22;19(1):100
pubmed: 30670035
Stat Methods Med Res. 2018 Jan;27(1):114-125
pubmed: 26711503
PLoS One. 2017 Sep 21;12(9):e0184174
pubmed: 28934233
J Clin Oncol. 2007 Jan 1;25(1):70-6
pubmed: 17194906
Diabetologia. 2013 Mar;56(3):476-83
pubmed: 23238788
Circulation. 2018 Feb 20;137(8):e30-e66
pubmed: 29437116
Health Educ Res. 2000 Oct;15(5):559-68
pubmed: 11184215
Breast Cancer Res Treat. 2017 Nov;166(1):185-193
pubmed: 28698973
Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1023-8
pubmed: 11240243
Ann Oncol. 2004 Apr;15(4):661-4
pubmed: 15033676
Cardiovasc Toxicol. 2007;7(2):61-6
pubmed: 17652805
Lancet. 2019 Sep 21;394(10203):1041-1054
pubmed: 31443926
Arch Intern Med. 2003 Jan 13;163(1):49-56
pubmed: 12523916
J Clin Oncol. 1998 Nov;16(11):3493-501
pubmed: 9817266
Breast Cancer Res Treat. 2012 Aug;135(1):281-9
pubmed: 22829398
Ann Plast Surg. 2018 Feb;80(2):188-192
pubmed: 29095189
J Am Heart Assoc. 2014 Apr 22;3(2):e000665
pubmed: 24755151
Cancer. 2018 Dec 1;124(23):4512-4519
pubmed: 30291812
J Am Heart Assoc. 2017 May 21;6(5):
pubmed: 28529208
JAMA. 2012 Nov 7;308(17):1775-84
pubmed: 23117778
Cancer. 2011 Jan 1;117(1):180-9
pubmed: 20939011
Stroke. 2005 May;36(5):1026-30
pubmed: 15802639
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):361-8
pubmed: 25425578
Breast Cancer Res Treat. 2011 Jun;127(3):729-38
pubmed: 21076864
Arch Pathol Lab Med. 1996 Jan;120(1):89-91
pubmed: 8554453
Breast Cancer Res. 2011 Jun 20;13(3):R64
pubmed: 21689398
Breast Cancer Res Treat. 2017 Aug;164(3):537-555
pubmed: 28503723
Public Health. 2018 Jan;154:1-10
pubmed: 29128730
Breast Cancer Res Treat. 2012 Feb;131(3):907-14
pubmed: 22042368
J Am Coll Cardiol. 1994 Nov 15;24(6):1515-22
pubmed: 7930284
Breast Cancer Res Treat. 2016 May;157(1):167-78
pubmed: 27116186
Compr Physiol. 2015 Jul 1;5(3):1517-40
pubmed: 26140726
J Natl Cancer Inst. 2014 Apr 28;106(5):
pubmed: 24777111
Prog Cardiovasc Dis. 2010 Jan-Feb;52(4):274-88
pubmed: 20109598
J Lat Psychol. 2016 May;4(2):114-129
pubmed: 27429867
Curr Epidemiol Rep. 2016;3:181-190
pubmed: 27547694
J Clin Oncol. 2006 Mar 20;24(9):1357-62
pubmed: 16549830
Am J Prev Med. 2013 May;44(5):550-60
pubmed: 23597822
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120